‹ All episodes

The BioInsights Podcast

Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take us

September 12, 2022 BioInsights Season 1 Episode 14
Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take us
The BioInsights Podcast
Chapters
1:23
Kris, tell us about your lab and the work you’re doing at the University of Wisconsin
7:27
How has Aldevron supported Kris’ work and how have both parties benefited?
9:28
Gene editing platforms, delivery technologies, in vivo cell tracking, and novel animal models - which of these is the biggest challenge and why?
14:00
What is the role of industry in tackling these challenges?
19:18
What is on the horizon for genomic medicine?
22:20
What is Danaher’s role in advancing genomic medicine?
More Info
The BioInsights Podcast
Insights into the editing of the human genome: where can novel non-viral polymeric delivery agents take us
Sep 12, 2022 Season 1 Episode 14
BioInsights

Tom Foti (Vice President and General Manager of the Protein Business Unit, Aldevron) and Dr Kris Saha (Associate Professor of Biomedical Engineering and Medical History and Bioethics, University of Wisconsin-Madison) discuss ongoing work in Dr Saha’s lab to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture. 

Apple Podcasts Spotify Amazon Music Overcast Castro Castbox +
Show Notes Chapter Markers

Tom Foti (Vice President and General Manager of the Protein Business Unit, Aldevron) and Dr Kris Saha (Associate Professor of Biomedical Engineering and Medical History and Bioethics, University of Wisconsin-Madison) discuss ongoing work in Dr Saha’s lab to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture. 

Kris, tell us about your lab and the work you’re doing at the University of Wisconsin
How has Aldevron supported Kris’ work and how have both parties benefited?
Gene editing platforms, delivery technologies, in vivo cell tracking, and novel animal models - which of these is the biggest challenge and why?
What is the role of industry in tackling these challenges?
What is on the horizon for genomic medicine?
What is Danaher’s role in advancing genomic medicine?